|
|
|
Kevin Buckley |
|
Partner |
|
St. Louis, Missouri |
|
 |
 |
Kevin Buckley is a partner in the Intellectual Property & Technology Practice in the St. Louis office. His practice focuses on biotechnology, life sciences, and pharmaceutical commercialization which includes patent preparation and prosecution, technology transfer and licensing, institutional collaborations, and intellectual property issues associated with venture finance. He also counsels his clients regarding pharmaceutical life-cycle management and regulatory matters pending before the FDA, USDA and EPA. Kevin's clients include Fortune 500 corporations, private research institutes, university systems, start-up companies, and entrepreneurs.
Previously, Mr. Buckley was the founder and President of Biotactica, LLC where he counseled c... » Read More Kevin Buckley is a partner in the Intellectual Property & Technology Practice in the St. Louis office. His practice focuses on biotechnology, life sciences, and pharmaceutical commercialization which includes patent preparation and prosecution, technology transfer and licensing, institutional collaborations, and intellectual property issues associated with venture finance. He also counsels his clients regarding pharmaceutical life-cycle management and regulatory matters pending before the FDA, USDA and EPA. Kevin's clients include Fortune 500 corporations, private research institutes, university systems, start-up companies, and entrepreneurs.
Previously, Mr. Buckley was the founder and President of Biotactica, LLC where he counseled clients in acquiring, protecting and commercializing biotechnologies and pharmaceutical technologies in the U.S. and abroad. Biotactica assisted clients obtain several million dollars in venture financing and developed commercialization strategies for life science entrepreneurs. Prior to that, he was with a large international law firm.
Before becoming an attorney, Kevin was a biochemist in both academics and industry where he investigated ribonucleic acid (RNA)-based therapeutics for treating viral infections and the role of purine nucleoside analogs in autoimmune diseases and cytokine mediated cell responses including apoptosis, rheumatoid arthritis, AIDS and cancers.
Kevin received a J.D. from the University of Pittsburgh where he was the Editor-in-Chief of The Pittsburgh Journal of Technology Law & Policy, and received a B.S. in Biochemistry from the University of California, San Diego where he was a Research Scholar.
In 2005, Kevin was named one of St. Louis Business Journal's "40 Under Forty," an annual award for becoming "a mover and shaker both in business and the St. Louis community." Since 2006, he has been listed in Who's Who in America and since 2007 in Who's Who in the World and Who's Who in American Law. Most recently, Kevin was selected as a member of "Who's Who in Technology" by the St. Louis Business Journal in July, 2007.
Kevin is a member of the Missouri Biotechnology Association, the International Society for Stem Cell Research, and the St. Louis Regional Chamber and Growth Association Plant and Life Science Network. He is a registered patent attorney with the U.S. Patent & Trademark Office and is admitted to practice law in Missouri. » Read Less Kevin Buckley is a partner in the Intellectual Property & Technology Practice in the St. Louis office. His practice focuses on biotechnology, life sciences, and pharmaceutical commercialization which includes patent preparation and prosecution, technology transfer and licensing, institutional collaborations, and intellectual property issues associated with venture finance. He also counsels his clients regarding pharmaceutical life-cycle management and regulatory matters pending before the FDA, USDA and EPA. Kevin's clients include Fortune 500 corporations, private research institutes, university systems, start-up companies, and entrepreneurs.
Previously, Mr. Buckley was the founder and President of Biotactica, LLC where he counseled clients in acquiring, protecting and commercializing biotechnologies and pharmaceutical technologies in the U.S. and abroad. Biotactica assisted clients obtain several million dollars in venture financing and developed commercialization strategies for life science entrepreneurs. Prior to that, he was with a large international law firm.
Before becoming an attorney, Kevin was a biochemist in both academics and industry where he investigated ribonucleic acid (RNA)-based therapeutics for treating viral infections and the role of purine nucleoside analogs in autoimmune diseases and cytokine mediated cell responses including apoptosis, rheumatoid arthritis, AIDS and cancers.
Kevin received a J.D. from the University of Pittsburgh where he was the Editor-in-Chief of The Pittsburgh Journal of Technology Law & Policy, and received a B.S. in Biochemistry from the University of California, San Diego where he was a Research Scholar.
In 2005, Kevin was named one of St. Louis Business Journal's "40 Under Forty," an annual award for becoming "a mover and shaker both in business and the St. Louis community." Since 2006, he has been listed in Who's Who in America and since 2007 in Who's Who in the World and Who's Who in American Law. Most recently, Kevin was selected as a member of "Who's Who in Technology" by the St. Louis Business Journal in July, 2007.
Kevin is a member of the Missouri Biotechnology Association, the International Society for Stem Cell Research, and the St. Louis Regional Chamber and Growth Association Plant and Life Science Network. He is a registered patent attorney with the U.S. Patent & Trademark Office and is admitted to practice law in Missouri.
|
|
Representative Technologies |
|
Representative technologies with which Kevin has assisted clients include: biopharmaceuticals, small molecule pharmaceuticals, and biologics (e.g., therapeutic polynucleotides and polypeptides including siRNA, shRNA, miRNA, ribozymes, antisense DNA, antibodies, related fragments, vaccines, and enzymes); RNA interference (RNAi); medical imaging compounds and diagnostic methods; polynucleotide and polypeptide detection and screening; bioinformatics; structural proteomics; three-dimensional molecular modeling and drug design; stem cells and therapeutic cloning methods; transgenic plants and animals; microorganism/cell culture equipment and methods; biofuels and agriculture biotechnologies; and wet and dry nanotechnologies.
Representative technologies with which Kevin has assisted clients include: biopharmaceuticals, small molecule pharmaceuticals, and biologics (e.g., therapeutic polynucleotides and polypeptides including siRNA, shRNA, miRNA, ribozymes, antisense DNA, antibodies, related fragments, vaccines, and enzymes); RNA interference (RNAi); medical imaging compounds and diagnostic methods; polynucleotide and polypeptide detection and screening; bioinformatics; structural proteomics; three-dimensional molecular modeling and drug design; stem cells and therapeutic cloning methods; transgenic plants and animals; microorganism/cell culture equipment and methods; biofuels and agriculture biotechnologies; and wet and dry nanotechnologies.
»Read Less |
|
Representative technologies with which Kevin has assisted clients include: biopharmaceuticals, small molecule pharmaceuticals, and biologics (e.g., therapeutic polynucleotides and polypeptides including siRNA, shRNA, miRNA, ribozymes, antisense DNA, antibodies, related fragments, vaccines, and enzymes); RNA interference (RNAi); medical imaging compounds and diagnostic methods; polynucleotide and polypeptide detection and screening; bioinformatics; structural proteomics; three-dimensional molecular modeling and drug design; stem cells and therapeutic cloning methods; transgenic plants and animals; microorganism/cell culture equipment and methods; biofuels and agriculture biotechnologies; and wet and dry nanotechnologies.
|
|
Representative Matters |
• Procuring foreign and domestic patents, registered trademarks and copyrights
• Counseling on the management and development of IPRs, identifying and patenting key innovations, and developing patent and trademark portfolios, some of which have encompassed fifty countries and hundreds of pending patent applications
• Preparing patent landscape reviews and freedom-to-operate opinions in some of the most crowded and competitive areas of patented life science technologies
• Drafting and negotiating complex patent, trademark and copyright licenses in the U.S. and abroad
• Drafting international agreements related to the distribution and protection of IPRs including strategic alliance, sponsored research, employment, comp... » Read More • Procuring foreign and domestic patents, registered trademarks and copyrights
• Counseling on the management and development of IPRs, identifying and patenting key innovations, and developing patent and trademark portfolios, some of which have encompassed fifty countries and hundreds of pending patent applications
• Preparing patent landscape reviews and freedom-to-operate opinions in some of the most crowded and competitive areas of patented life science technologies
• Drafting and negotiating complex patent, trademark and copyright licenses in the U.S. and abroad
• Drafting international agreements related to the distribution and protection of IPRs including strategic alliance, sponsored research, employment, compensation and confidentiality agreements
• Drafting international agreements related to life science development and product manufacturing including collaboration, distribution, material transfer, and joint commercialization agreements
• Conducting due diligence related to initial public offerings, venture capital, and other investments, mergers and acquisitions
• Preparing patent infringement and validity analysis and opinions
• Conducting patent interferences and appeals, re-examinations, reissues and oppositions
• Litigating patent, trademark, copyright and related matters in district and appellate courts
• Advising on regulatory compliance with respect to the Food and Drug Administration (FDA), U.S. Department of Agriculture (USDA) and the Environmental Protection Agency (EPA) regulations
»Read Less |
|
• Procuring foreign and domestic patents, registered trademarks and copyrights
• Counseling on the management and development of IPRs, identifying and patenting key innovations, and developing patent and trademark portfolios, some of which have encompassed fifty countries and hundreds of pending patent applications
• Preparing patent landscape reviews and freedom-to-operate opinions in some of the most crowded and competitive areas of patented life science technologies
• Drafting and negotiating complex patent, trademark and copyright licenses in the U.S. and abroad
• Drafting international agreements related to the distribution and protection of IPRs including strategic alliance, sponsored research, employment, compensation and confidentiality agreements
• Drafting international agreements related to life science development and product manufacturing including collaboration, distribution, material transfer, and joint commercialization agreements
• Conducting due diligence related to initial public offerings, venture capital, and other investments, mergers and acquisitions
• Preparing patent infringement and validity analysis and opinions
• Conducting patent interferences and appeals, re-examinations, reissues and oppositions
• Litigating patent, trademark, copyright and related matters in district and appellate courts
• Advising on regulatory compliance with respect to the Food and Drug Administration (FDA), U.S. Department of Agriculture (USDA) and the Environmental Protection Agency (EPA) regulations
|
|
Presentations and Publications |
• BioCommercialization Blog, available at http://www.biocommercialization.com.
• Presenter, ABCs of Commercialization, 6th Corn Utilization and Technology Conference, Kansas City, Missouri (June 3, 2008).
• Presenter, Opportunities in Emerging Geographies, 2nd Annual Global Healthcare Investing Conference, Cleveland, Ohio (April 30, 2008).
• Interviewed for feature segment related to biotechnology commercialization and pharmaceutical commercialization, Conversation with Lee Presser (television broadcast September 10 & 17, 2007).
• Presenter, Bringing Overseas Start-Ups Into U.S., Inaugural Global Healthcare Investing Conference, Cleveland, Ohio (June 21, 2007).
• Presenter, Leveraging the Revenue Potential of Patents Thr... » Read More • BioCommercialization Blog, available at http://www.biocommercialization.com.
• Presenter, ABCs of Commercialization, 6th Corn Utilization and Technology Conference, Kansas City, Missouri (June 3, 2008).
• Presenter, Opportunities in Emerging Geographies, 2nd Annual Global Healthcare Investing Conference, Cleveland, Ohio (April 30, 2008).
• Interviewed for feature segment related to biotechnology commercialization and pharmaceutical commercialization, Conversation with Lee Presser (television broadcast September 10 & 17, 2007).
• Presenter, Bringing Overseas Start-Ups Into U.S., Inaugural Global Healthcare Investing Conference, Cleveland, Ohio (June 21, 2007).
• Presenter, Leveraging the Revenue Potential of Patents Through Commercialization, Mumbai, India (November 27, 2006).
• Presenter, Streamlining AgBio Regulation - Shifting Public Policy and Statutory Design for Multi-Trait and Predictably Expressed Gene Packages, Second Generation Ag Biotech Conference, Washington, D.C (March 16, 2005).
• Co-author, Standing at the Molecular Crossroads: Report on Nanotechnology in Missouri, White Paper requested by the Missouri Department of Economic Development (September, 2003).
• Presenter, Copyright: Frequently Asked Questions by Illustrators, St. Louis Artists Guild - Volunteer Lawyers and Accountants for the Arts (September 10, 2002).
• Co-author, Attack of the Clones... and the Issues of Clones, 3 Colum. Sci. & Tech. L. Rev. 3 (May, 2002), available at http://www.stlr.org/cite.cgi?volume=3&article=3.
• Co-presenter, Full, Clear, Concise and Exact. What You Should Know About the Patent Written Description Requirement: A Practitioner's Roundtable, Bar Association of Metropolitan St. Louis (February 26, 2002).
• Co-author, Survey of Missouri Employment Privacy Law, 2001 LDRC 50-State Survey Of Employment Libel And Privacy Law, 589-98 (2001).
»Read Less |
• BioCommercialization Blog, available at http://www.biocommercialization.com.
• Presenter, ABCs of Commercialization, 6th Corn Utilization and Technology Conference, Kansas City, Missouri (June 3, 2008).
• Presenter, Opportunities in Emerging Geographies, 2nd Annual Global Healthcare Investing Conference, Cleveland, Ohio (April 30, 2008).
• Interviewed for feature segment related to biotechnology commercialization and pharmaceutical commercialization, Conversation with Lee Presser (television broadcast September 10 & 17, 2007).
• Presenter, Bringing Overseas Start-Ups Into U.S., Inaugural Global Healthcare Investing Conference, Cleveland, Ohio (June 21, 2007).
• Presenter, Leveraging the Revenue Potential of Patents Through Commercialization, Mumbai, India (November 27, 2006).
• Presenter, Streamlining AgBio Regulation - Shifting Public Policy and Statutory Design for Multi-Trait and Predictably Expressed Gene Packages, Second Generation Ag Biotech Conference, Washington, D.C (March 16, 2005).
• Co-author, Standing at the Molecular Crossroads: Report on Nanotechnology in Missouri, White Paper requested by the Missouri Department of Economic Development (September, 2003).
• Presenter, Copyright: Frequently Asked Questions by Illustrators, St. Louis Artists Guild - Volunteer Lawyers and Accountants for the Arts (September 10, 2002).
• Co-author, Attack of the Clones... and the Issues of Clones, 3 Colum. Sci. & Tech. L. Rev. 3 (May, 2002), available at http://www.stlr.org/cite.cgi?volume=3&article=3.
• Co-presenter, Full, Clear, Concise and Exact. What You Should Know About the Patent Written Description Requirement: A Practitioner's Roundtable, Bar Association of Metropolitan St. Louis (February 26, 2002).
• Co-author, Survey of Missouri Employment Privacy Law, 2001 LDRC 50-State Survey Of Employment Libel And Privacy Law, 589-98 (2001).
|
 |
